Tuesday, 11 September 2012

Fareston 60mg Tablets





1. Name Of The Medicinal Product



Fareston 60 mg tablets


2. Qualitative And Quantitative Composition



Each tablet contains 60 mg toremifene (as citrate).



Excipients: 30 mg lactose per tablet.



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Tablet.



White, round, flat, bevelled edge tablet with TO 60 on one side.



4. Clinical Particulars



4.1 Therapeutic Indications



First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.



Fareston is not recommended for patients with estrogen receptor negative tumours.



4.2 Posology And Method Of Administration



Posology



The recommended dose is 60 mg daily.



Renal impairment



No dose adjustment is needed in patients with renal insufficiency.



Hepatic impairment



Toremifene should be used cautiously in patients with liver impairment(see section 5.2).



Pediatric use



There is no relevant indication for use of Fareston in children.



Method of administration



Toremifene is administered orally. Toremifene can be taken with or without food.



4.3 Contraindications



- Pre-existing endometrial hyperplasia and severe hepatic failure are contra-indications in long-term use of toremifene.



- Hypersensitivity to toremifene or to any of the excipients.



- Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to toremifene, in the form of QT prolongation. For reasons of drug safety, toremifene is therefore contraindicated in patients with:





 


- Congenital or documented acquired QT prolongation



- Electrolyte disturbances, particularly in uncorrected hypokalaemia



- Clinically relevant bradycardia



- Clinically relevant heart failure with reduced left-ventricular ejection fraction



- Previous history of symptomatic arrhythmias.



Toremifene should not be used concurrently with other drugs that prolong the QT interval (see also section 4.5).



4.4 Special Warnings And Precautions For Use



Gynaecological examination should be performed before treatment administration, closely looking at pre-existing endometrial abnormality. Afterwards gynaecological examination should be repeated at least once a year. Patients with additional risk of endometrial cancer, e.g. patients suffering from hypertension or diabetes, having high BMI (>30) or history of hormone replacement therapy should be closely monitored (see also section 4.8).



Patients with a history of severe thromboembolic disease should generally not be treated with toremifene(see also section 4.8).



Fareston has been shown to prolong the QTc interval on the electrocardiogram in some patients in a dose-related manner. The following information regarding QT-prolongation is of special importance (for contraindications see section 4.3).



A QT clinical study with a 5-arm parallel design (placebo, moxifloxacin 400 mg, toremifene 20 mg, 80 mg, and 300 mg) has bee performed in 250 male patients to characterize the effects of toremifene on the QTc interval duration. The results of this study show a clear positive effect of toremifine in the 80 mg group with mean prolongations of 21 – 26 ms. Regarding the 20 mg group, this effect is significant as well, according to ICH guidelines, with upper confidence interval of 10 – 12 ms. These results strongly suggest an important dose-dependent effect. As women tend to have a longer baseline QTc interval compared with men, they may be more sensitive to QTc-prolonging medications. Elderly patients may also be more susceptible to drug-associated effects on the QT interval.



Fareston should be used with caution in patients with ongoing proarrhythmic conditions (especially elderly patients) such as acute myocardial ischaemia or QT prolongation as this may lead to an increased risk for ventricular arrhythmias (incl. Torsade de pointes) and cardiac arrest (see also section 4.3). If signs or symptoms that may be associated with cardiac arrhythmia occur during treatment with Fareston,treatment should be stopped and an ECG should be performed.



If the QTc interval is>500 ms, Fareston should not be used.



Hypercalcemia may occur at the beginning of toremifene treatment in patients with bone metastasis and thus these patients should be closely monitored.



There are no systematic data available from patients with labile diabetes, from patients with severely altered performance status or from patients with cardiac failure.



Fareston tablets contain lactose (30 mg/tablet). Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



An additive effect on QT interval prolongation between Fareston and the following drugs and other medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias, including Torsade de points. Therefore co-administration of Fareston with any of the following medicinal products is contraindicated (see also section 4.3):



- antiarrhythmics class 1A (e.g. quinidine, hydroquinidine, disopyramide) or



- antiarrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide).



- neuroleptics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride).



- certain antimimicrobials agents (moxifloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine).



- certain antihistaminics (terfenadine, astemizole, mizolastine).



- others (cisapride, vincamine IV, bepridil, diphemanil).



Drugs which decrease renal calcium excretion, e.g. thiazide, diuretics, may increase the risk of hypercalcaemia.



Enzyme inducers, like phenobarbital, phenytoin and carbamazepine, may increase the rate of toremifene metabolism thus lowering the steady-state concentration in serum. In such cases doubling of the daily dose may be necessary.



There is a known interaction between anti-estrogens and warfarin-type anticoagulants leading to a seriously increased bleeding time. Therefore, the concomitant use of toremifene with such drugs should be avoided.



Theoretically the metabolism of toremifene is inhibited by drugs known to inhibit the CYP 3A enzyme system which is reported to be responsible for its main metabolic pathways. Examples of such drugs are ketoconazole and similar antimycotics, erythromycin and troleandomycin. Concomitant use of those drugs with toremifene should be carefully considered.



4.6 Pregnancy And Lactation



Toremifene is recommended for postmenopausal patients.



There are no adequate data from the use of Fareston in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.



Fareston should not be used during pregnancy.



In rats, decreased body weight gain of the offspring during lactation was observed.



Fareston should not be used during lactation.



4.7 Effects On Ability To Drive And Use Machines



Toremifene has no influence on the ability to drive and use machines.



4.8 Undesirable Effects



The most frequent adverse reactions are hot flushes, sweating, uterine bleeding, leukorrhea,fatigue,nausea,rash,itching,dizziness and depression. The reactions are usually mild and mostly due to the hormonal action of toremifene.



The frequencies of the adverse reactions are classified as follows:



Very common (



Common (



Uncommon (



Rare (



Very rare (<1/10,000), not known (cannot be estimated from the available data).
























































































System organ class




Very Common




Common




Uncommon




Rare




Very rare




Neoplasms benign, malignant and unspecified (including cysts and polyps)




 



 




 



 




 



 




 



 




endometrial cancer




Metabolism and nutrition disorders




 



 




 



 




loss of appetite




 



 




 



 




Psychiatric disorders




 



 




depression




Insomnia




 



 




 



 




Nervous system disorders




 



 




dizziness




headache




 



 




 



 




Eye disorders




 



 




 



 




 



 




 



 




transient corneal opacity




Ear and labyrinth disorders




 



 




 



 




 



 




vertigo




 



 




Vascular disorders




hot flushes




 



 




thromboembolic events




 



 




 



 




Respiratory, thoracic and mediastinal disorders




 



 




 



 




dyspnoea




 



 




 



 




Gastrointestinal disorders




 



 




nausea, vomiting




constipation




 



 




 



 




Hepatobiliary disorders




 



 




 



 




 



 




increase of transaminases




jaundice




Skin and subcutaneous tissue disorders




sweating




rash, itching




 



 




 



 




alopecia




Reproductive system and breast disorders




 



 




uterine bleeding leukorrhea




endometrial hypertrophy




endometrial polyps




endometrial hyperplasia.




General disorders and administration site conditions




 



 




fatigue oedema




weight increase




 



 




 



 



Thromboembolic events include deep venous thrombosis, thrombophlebitis and pulmonary embolism (see also section 4.4).



Toremifene treatment has been associated with changes in liver enzyme levels (increases of transaminases) and in very rare occasions with more severe liver function abnormalities (jaundice).



A few cases of hypercalcaemia have been reported in patients with bone metastases at the beginning of toremifene treatment.



Endometrial hypertrophy may develop during the treatment due to the partial estrogenic effect of toremifene. There is a risk of increased endometrial changes including hyperplasia, polyps and cancer. This may be due to the underlying mechanism/estrogenic stimulation (see also section 4.4).



Fareston increases the QT interval in a dose-related manner (see also section 4.4).



4.9 Overdose



Vertigo, headache and dizziness were observed in healthy volunteer studies at daily dose of 680 mg. The dose-related QTc interval prolongation potential of Fareston should also be taken into account in cases of overdose. There is no specific antidote and the treatment is symptomatic



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Anti-estrogens, ATC code: L02BA02



Toremifene is a nonsteroidal triphenylethylene derivative. As other members of this class, e.g. tamoxifen and clomifene, toremifene binds to estrogen receptors and may produce estrogenic, anti-estrogenic or both effects, depending upon the duration of treatment, animal species, gender, target organ and variable selected. In general, however, nonsteroidal triphenylethylene derivatives are predominantly anti-estrogenic in rats and man and estrogenic in mice.



In post-menopausal breast cancer patients, toremifene treatment is associated with modest reductions in both total serum cholesterol and low density lipoprotein (LDL).



Toremifene binds specifically to estrogen receptors, competitively with estradiol, and inhibits oestrogen-induced stimulation of DNA synthesis and cell replication. In some experimental cancers and/or using high-dose, toremifene displays anti-tumour effects which are not estrogen-dependent.



The anti-tumour effect of toremifene in breast cancer is mainly due to the anti-estrogenic effect, although other mechanisms (changes in oncogene expression, growth factor secretion, induction of apoptosis and influence on cell cycle kinetics) may also be involved in the anti-tumour effect.



5.2 Pharmacokinetic Properties



Absorption



Toremifene is readily absorbed after oral administration. Peak concentrations in serum are obtained within 3 (range 2 - 5) hours. Food intake has no effect on the extent of absorption but may delay the peak concentrations by 1.5 - 2 hours. The changes due to food intake are not clinically significant.



Distribution



The serum concentration curve can be described by a biexponential equation. The half-life of the first (distribution) phase is 4 (range 2 - 12) hours, and of the second (elimination) phase 5 (range 2 - 10 ) days. The basal disposition parameters (CL and V) could not be estimated due to the lack of intravenous study. Toremifene binds extensively (> 99.5 %) to serum proteins, mainly to albumin. Toremifene obeys linear serum kinetics at oral daily doses between 11 and 680 mg. The mean concentration of toremifene at steady-state is 0.9 (range 0.6 - 1.3) µg/ml at the recommended dose of 60 mg per day.



Metabolism



Toremifene is extensively metabolised. In human serum the main metabolite is N-demethyltoremifene with mean half-life of 11 (range 4 - 20) days . Its steady-state concentrations are about twice compared to those of the parent compound. It has similar anti-estrogenic, albeit weaker anti-tumour activity than the parent compound.



It is bound to plasma proteins even more extensively than toremifene, the protein bound fraction being> 99.9 %. Three minor metabolites have been detected in human serum: (deaminohydroxy)toremifene, 4-hydroxytoremifene, and N,N-didemethyltoremifene. Although they have theoretically interesting hormonal effects, their concentrations during toremifene treatment are too low to have any major biological importance.



Elimination



Toremifene is eliminated mainly as metabolites to the faeces. Enterohepatic circulation can be expected. About 10 % of the administered dose is eliminated via urine as metabolites. Owing to the slow elimination, steady-state concentrations in serum are reached in 4 to 6 weeks.



Characteristics in patients



Clinical anti-tumour efficacy and serum concentrations have no positive correlation at the recommended daily dose of 60 mg.



No information is available concerning polymorphic metabolism. Enzyme complex, known to be responsible for the metabolism of toremifene in humans, is cytochrome P450-dependent hepatic mixed function oxidase. The main metabolic pathway, N-demethylation, is mediated mainly by CYP 3A.



Pharmacokinetics of toremifene were investigated in an open study with four parallel groups of ten subjects: normal subjects, patients with impaired (mean AST 57 U/L - mean ALT 76 U/L - mean gamma GT 329 U/L) or activated liver function (mean AST 25 U/L - mean ALT 30 U/L - mean gamma GT 91 U/L - patients treated with antiepileptics) and patients with impaired renal function (creatinine: 176 µmol/L). In this study the kinetics of toremifene in patients with impaired renal function were not significantly altered as compared to normal subjects. The elimination of toremifene and its metabolites was significantly increased in patients with activated liver function and decreased in patients with impaired liver function.



5.3 Preclinical Safety Data



The acute toxicity of toremifene is low with LD-50 in rats and mice of more than 2000 mg/kg. In repeated toxicity studies the cause of death in rats is gastric dilatation. In the acute and chronic toxicity studies most of the findings are related to the hormonal effects of toremifene. The other findings are not toxicologically significant. Toremifene has not shown any genotoxicity and has not been found to be carcinogenic in rats. In mice, estrogens induce ovarian and testicular tumours as well as hyperostosis and osteosarcomas. Toremifene has a species-specific estrogen-like effect in mice and causes similar tumours. These findings are postulated to be of little relevance for the safety in man, where toremifene acts mainly as an anti-estrogen.



Non-clinical in vitro and in vivo studies have evidenced the potential of toremifene and its metabolite to prolong cardiac repolarisation and this can be attributed to the blockade of hERG channels.



In vivo, high plasma concentrations in monkeys caused a 24% prolongation in QTc, which is in line with QTc findings in humans.



It is also to be noted that the Cmax observed in the monkeys (1800 ng/ml)is two-fold compared to the mean Cmax observed in humans at a daily dose of 60 mg.



Action potential studies in isoloated rabbit heart have shown that toremifene induce cardiac electrophysiological changes which start to develop at concentrations approximately 10 fold compared to the calculated free therapeutic plasma concentration in human.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Maize starch



Lactose



Povidone



Sodium starch glycolate



Magnesium stearate



Cellulose, microcrystalline



Silica, colloidal anhydrous



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



5 years.



6.4 Special Precautions For Storage



This medicinal product does not require any special storage conditions.



6.5 Nature And Contents Of Container



Green PVC foil and aluminium foil blister in a cardboard box.



Package sizes: 30 and 100 tablets.



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



No special requirements.



7. Marketing Authorisation Holder



Orion Corporation



Orionintie 1



FIN-02200 Espoo



Finland



8. Marketing Authorisation Number(S)



EU/1/96/004/001



EU/1/96/004/002



9. Date Of First Authorisation/Renewal Of The Authorisation



14 February 1996/2 February 2006



10. Date Of Revision Of The Text



January 2009



Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/




Saturday, 8 September 2012

Ophthalmic diagnostic agents


A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

Ophthalmic diagnostic agents are given intravenously to perform diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. A few preparations also contain a local anesthetic to reduce pain in the nerves of the eyes.

See also

Medical conditions associated with ophthalmic diagnostic agents:

  • Diagnosis and Investigation
  • Ophthalmic Surgical Staining

Drug List:

Wednesday, 5 September 2012

Lioresal


Generic Name: Baclofen
Class: GABA-derivative Skeletal Muscle Relaxants
VA Class: MS200
Chemical Name: 4-Amino-3-(4-chlorophenyl)-butanoic acid
Molecular Formula: C10H12ClNO2
CAS Number: 1134-47-0


  • Intrathecal Baclofen Withdrawal


  • Abrupt discontinuation of intrathecal baclofen may result in seizures, high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity; in rare cases, progression to rhabdomyolysis, multisystem organ failure, and death may occur.113




  • Give careful attention to programming and monitoring of infusion system, refill scheduling and procedures, and pump alarms to prevent abrupt discontinuance.113 (See Warnings under Cautions.)




  • Advise patients and caregivers of the importance of keeping scheduled refill visits and of the early signs and symptoms of baclofen withdrawal.113




  • Give special attention to patients at apparent risk for withdrawal (e.g., spinal cord injury at T6 level or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen).113




Introduction

Skeletal muscle relaxant and antispasticity agent; a GABA derivative.113 128


Uses for Lioresal


Spasticity


Oral management of spasticity and its sequelae secondary to severe chronic disorders such as multiple sclerosis and other types of spinal cord lesions.112 128


Intrathecal management of severe spasticity of spinal cord origin in patients who do not tolerate or respond adequately to oral baclofen;109 110 113 114 115 116 117 118 119 120 considered an alternative to destructive neurosurgical procedures.113 Also, intrathecal management of intractable spasticity secondary to severe chronic disorders such as multiple sclerosis and other types of spinal diseases such as spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy.112


Intrathecal management of severe spasticity of cerebral origin, including cerebral palsy and acquired brain injury;113 121 122 123 124 125 126 127 considered an alternative to destructive neurosurgical procedures.113 Patients with spasticity secondary to traumatic brain injury should wait ≥1 year after the injury before considering long-term intrathecal baclofen therapy.113


Efficacy not established for the management of stroke or Parkinson's disease; use not recommended.128


Lioresal Dosage and Administration


General



  • Clinical goal is to maintain muscle tone as close to normal as possible and to minimize frequency and severity of spasms without inducing intolerable adverse effects.113 115 May be important to maintain some degree of muscle tone and allow occasional spasms to help support circulatory function, minimize risk of DVT occurrence, and optimize activities of daily living and ease of care.113




  • Individualize dosage according to patient’s requirements and response; use lowest dosage that produces optimum response without adverse effects.113 128




  • Some patients require 1–2 months of oral treatment for full benefit.b If benefits are not evident after a reasonable trial period, discontinue therapy by slowly reducing daily dosage.128




  • Prior to implantation of pump for chronic intrathecal baclofen therapy, patient must exhibit positive response (clinically important decrease in muscle tone and/or frequency and/or severity of spasms over 4- to 8-hour observation period) to initial intrathecal test dose(s) (screening phase).110 113 115




  • Tolerance may develop during chronic intrathecal baclofen therapy.113 115 No firm recommendations regarding amelioration of tolerance; patients occasionally have been hospitalized and intrathecal baclofen dosage decreased gradually over 2- to 4-week period, during which baclofen was alternated with other methods of spasticity management.113 115 Sensitivity to baclofen may return after a few days, and continuous intrathecal baclofen therapy may be resumed at the previously effective initial dosage.113 115



Administration


Administer orally or intrathecally.113 127 128


Baclofen injection for intrathecal administration is not recommended or intended for IV, IM, sub-Q, or epidural administration.113 115


Avoid abrupt discontinuance (because of risk of precipitating withdrawal).113 127 128 Reduce dosage slowly when discontinuing drug, except for serious adverse reactions.113 128 (See Warnings under Cautions.)


Oral Administration


Administer orally 3 times daily.128


Intrathecal Administration


For solution and drug compatibility information, see Compatibility under Stability.


Administer test dose(s) during screening phase by direct intrathecal injection (via lumbar puncture or catheter) over ≥1 minute employing barbotage.110 113 114 115


Administer maintenance regimen by continuous intrathecal infusion into a lumbar intrathecal space via an implantable controlled-infusion device (e.g., Medtronic SynchroMed pump).110 113 114 115


Consult manufacturer's labeling for specialized administration techniques.113


Consult manual provided by manufacturer of implantable infusion device for specific instructions and precautions for programming pump and/or refilling reservoir and for drug delivery specifications.113


Dilution

To prepare test doses for screening phase, use 1-mL ampuls containing 50 mcg of baclofen without further dilution.113 Ampuls are for single use only; discard any unused portion.113


For maintenance therapy in patients receiving concentrations other than the commercially available strengths (i.e., 0.5 or 2 mg/mL), injection concentrate must be diluted with sterile, preservative-free 0.9% sodium chloride injection.113


Rate of Administration

Test dose(s): Direct intrathecal injection by barbotage over ≥1 minute.113


Maintenance regimen: Continuous intrathecal infusion.113


Dosage


Pediatric Patients


Spasticity

Oral

Children ≥12 Years of Age: Initially, 5 mg 3 times daily.128 Increase daily dosage by 15 mg (in 3 divided doses) at 3-day intervals (i.e., 5 mg 3 times daily for 3 days, then 10 mg 3 times daily for 3 days, then 15 mg 3 times daily for 3 days, then 20 mg 3 times daily for 3 days) until optimum effect is achieved.128


Usual dosage in children ≥12 years of age is 40–80 mg daily.128


Screening for Response to Intrathecal Baclofen in Severe Spasticity

Intrathecal

Administer test dose of 50 mcg (1 mL of 50-mcg/mL solution) into intrathecal space by barbotage over ≥1 minute; may consider an initial dose of 25 mcg in very small children.113


If response observed at 4–8 hours after initial test dose is less than desired, administer a second test dose of 75 mcg (1.5 mL of a 50-mcg/mL solution) 24 hours after first test dose.113


If response remains inadequate, administer a final test dose of 100 mcg (2 mL of a 50-mcg/mL solution) 24 hours after second test dose.113


Patients not responding to 100-mcg test dose are not candidates for chronic intrathecal therapy.110 113 115


Maintenance Therapy for Severe Spasticity

Intrathecal

Following establishment of responsiveness to intrathecal baclofen, administer initial daily dose over 24 hours.113 115


Initial daily dose is twice the test dose that produced a positive response with a duration not >8 hours.113 115 If positive response to test dose persisted >8 hours, initial dose is the same as the test dose that produced a positive response.113 115


Following the initial infusion dose in children with spasticity of spinal cord or cerebral origin, increase daily dosage slowly (by 5–15% increments at 24-hour intervals) until desired clinical response is achieved.113 115


May need to adjust maintenance dosage often during initial months of therapy.113 115 During periodic pump refills, increase the 24-hour dose by up to 10–40% in patients with spasticity of spinal cord origin or up to 5–20% in those with spasticity of cerebral origin as necessary to maintain adequate control of symptoms.113 115 In patients who develop intolerable adverse effects, reduce the 24-hour dose by 10–20%.113 115


Patients achieving relatively satisfactory relief may derive further benefit from more complex dosing schedules.110 113 115 For example, patients who commonly experience an exacerbation of spasticity that disrupts sleep may require a 20% increase in the hourly infusion rate (programmed to begin approximately 2 hours before the time of desired clinical benefit).110 113 115


Maintenance dosage in most children >12 years of age: 300–800 mcg daily (range: 12–2003 mcg daily) in those with spasticity of spinal cord origin;110 113 115 90–703 mcg daily (range: 22–1400 mcg daily) in those with spasticity of cerebral origin.113


Average maintenance dosage in children <12 years of age: 274 mcg daily (range: 24–1199 mcg daily).113


Adults


Spasticity

Oral

Initially, 5 mg 3 times daily.128 Increase daily dosage by 15 mg (in 3 divided doses) at 3-day intervals (i.e., 5 mg 3 times daily for 3 days, then 10 mg 3 times daily for 3 days, then 15 mg 3 times daily for 3 days, then 20 mg 3 times daily for 3 days) until optimum effect is achieved.128


Usual dosage is 40–80 mg daily.128


Screening for Response to Intrathecal Baclofen in Severe Spasticity

Intrathecal

Administer test dose of 50 mcg (1 mL of 50-mcg/mL solution) into intrathecal space by barbotage over ≥1 minute.113


If response observed at 4–8 hours after initial test dose is less than desired, administer a second test dose of 75 mcg (1.5 mL of a 50-mcg/mL solution) 24 hours after first test dose.113


If response remains inadequate, administer a final test dose of 100 mcg (2 mL of a 50-mcg/mL solution) 24 hours after second test dose.113


Patients not responding to 100-mcg test dose are not candidates for chronic intrathecal therapy.110 113 115


Maintenance Therapy for Severe Spasticity

Intrathecal

Following establishment of responsiveness to intrathecal baclofen, administer initial daily dose over 24 hours.113 115


Initial daily dose is twice the test dose that produced a positive response with a duration not >8 hours.113 115 If positive response to test dose persisted >8 hours, initial dose is the same as the test dose that produced a positive response.113 115


Following the initial infusion dose, increase daily dosage slowly until the desired clinical response is achieved: increase dosage by 10–30% increments at 24-hour intervals in adults with spasticity of spinal cord origin and by 5–15% increments at 24-hour intervals in adults with spasticity of cerebral origin.113 115


May need to adjust maintenance dosage often during initial months of therapy.113 115 During periodic pump refills, increase the 24-hour dose by up to 10–40% in patients with spasticity of spinal cord origin or up to 5–20% in those with spasticity of cerebral origin as necessary to maintain adequate control of symptoms.113 115 In patients who develop intolerable adverse effects, reduce the 24-hour dose by 10–20%.113 115


Patients achieving relatively satisfactory relief may derive further benefit from more complex dosing schedules.110 113 115 For example, patients who commonly experience an exacerbation of spasticity that disrupts sleep may require a 20% increase in the hourly infusion rate (programmed to begin approximately 2 hours before the time of desired clinical benefit).110 113 115


Maintenance dosage in most patients: 300–800 mcg daily (range: 12–2003 mcg daily) in those with spasticity of spinal cord origin;110 113 115 90–703 mcg daily (range: 22–1400 mcg daily) in those with spasticity of cerebral origin.113


Prescribing Limits


Pediatric Patients


Spasticity

Oral

Some clinicians suggest that daily dosages up to 150 mg are well tolerated and provide additional therapeutic benefit in some patients; however, one manufacturer states that dosage should not exceed 80 mg daily (20 mg 4 times daily).128


Intrathecal

Limited experience with maintenance dosages >1000 mcg daily.113


Adults


Spasticity

Oral

Some clinicians suggest that daily dosages up to 150 mg are well tolerated and provide additional therapeutic benefit in some patients; however, one manufacturer states that dosage should not exceed 80 mg daily (20 mg 4 times daily).128


Intrathecal

Limited experience with maintenance dosages >1000 mcg daily.113


Special Populations


Renal Impairment


Reduction of oral or intrathecal dosage may be necessary.113 128


Geriatric Patients


Increase oral dosage more gradually.b


Patients with Psychiatric or Brain Disorders


Increase oral dosage more gradually.b


Cautions for Lioresal


Contraindications



  • Known hypersensitivity to baclofen or any ingredient in the formulation.113 128



Warnings/Precautions


Warnings


Abrupt Withdrawal of Oral Therapy

Abrupt discontinuance of oral baclofen may result in hallucinations and seizures.127 128


Abrupt Withdrawal of Intrathecal Therapy

Abrupt discontinuance of intrathecal baclofen may result in seizures, high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity; in rare cases, progression to rhabdomyolysis, multisystem organ failure, and death may occur.113


Symptoms usually appear within hours to days following interruption of therapy.113 Early symptoms may include return of baseline spasticity, pruritus, hypotension, and paresthesias.113 Advanced withdrawal syndrome may resemble autonomic dysreflexia, sepsis, malignant hyperthermia, neuroleptic malignant syndrome, or other conditions associated with a hypermetabolic state or widespread rhabdomyolysis.113


Rapid, accurate diagnosis and treatment in emergency room or intensive care setting are needed to prevent potentially life-threatening CNS and systemic effects.113


Restore intrathecal baclofen therapy at or near the dosage used prior to interruption.113


If reinstitution of intrathecal delivery is delayed, drugs that enhance GABA effects (e.g., oral or enteral baclofen; oral, enteral, or IV benzodiazepines) may prevent potentially fatal sequelae.113 However, do not rely on oral or enteral baclofen alone to halt progression of intrathecal baclofen withdrawal.113


Experience in Intrathecal Administration

Should be administered intrathecally only by qualified individuals familiar with the administration techniques and patient management problems.113 115


Initial test for responsiveness to intrathecal baclofen, implantation of pump, and subsequent periods of dosage titration must be performed in a medically supervised setting that is adequately equipped for the management of potential complications; resuscitative equipment should be readily available.113 115


Risks of Intrathecal Administration

Potentially life-threatening CNS depression, cardiovascular collapse, and respiratory failure reported following intrathecal administration.113 Fatalities (including 2 cases of sudden and unexpected death occurring within 2 weeks of pump implantation) reported rarely during intrathecal therapy; however, manufacturer states that causal relationship not established.113


Patients, caregivers, and health-care providers should receive adequate information regarding the risks of intrathecal baclofen therapy, including information on recognition and management of potential overdosage and proper care of the pump and catheter insertion site.113


Management of Controlled Infusion Device

Delay implantation of controlled-infusion device until response to test dose(s) is adequately evaluated.113


Familiarization with the implantable infusion device (e.g., dilution and delivery rates, instructions and precautions for pump programming and refilling) is essential.113


Fill drug reservoir under aseptic conditions, following the directions provided by the device’s manufacturer; only fully trained and qualified personnel should fill reservoir.113 Follow proper refill frequency to avoid depletion of drug reservoir during use.113 114 115


Monitor patient carefully, particularly during the initial phase of pump use, dosage titration, and reservoir refilling to ensure an acceptable, reasonably stable response.113


Any sudden increase in dosage requirement should suggest the possibility of pump and/or catheter malfunction.113 If no increase in response is observed with upward titration of dosage, check pump function and catheter patency.113 115


Intrathecal Baclofen Overdose

Signs of intrathecal baclofen overdose may appear suddenly or over a period of time.113


Acute, massive overdose may present as coma.113


Less sudden and/or less severe forms of overdose may present with drowsiness, lightheadedness, dizziness, somnolence, respiratory depression, seizures, rostral progression of hypotonia, and loss of consciousness progressing to coma.113


Overdose generally related to pump malfunction or dosing error.113


If overdose appears likely, immediately take patient to hospital for assessment and emptying of pump reservoir.113


Fill pump with extreme caution; refill only through the pump reservoir.113 Some pumps are equipped with a catheter access port that allows direct access to the intrathecal catheter; direct injection into this catheter may cause life-threatening overdose.113


General Precautions


Autonomic Dysreflexia

Use intrathecal baclofen with caution in patients with a history of autonomic dysreflexia; the presence of nociceptive stimuli or abrupt withdrawal of therapy may precipitate episode of dysreflexia.113


CNS Depression

Performance of activities requiring mental alertness may be impaired.113 128


Concurrent use of other CNS depressants may potentiate CNS depression.113 128 (See Specific Drugs under Interactions.)


Maintenance of Muscle Tone

Use with caution and titrate dosage carefully when spasticity is necessary to sustain upright posture and balance in locomotion or whenever spasticity is used to obtain optimal function and care.113 128


Neurological Disorders

Possible exacerbation of psychotic disorders, schizophrenia, or confusional states; use with caution and monitor such patients carefully.113


Possible deterioration in seizure control and EEG in epileptic patients; monitor patient’s clinical state and EEG at regular intervals.128


Concomitant Antispasmodic Therapies

If intrathecal therapy is to be employed, attempt to discontinue concomitant oral antispasmodic drugs to avoid possible overdose and drug interactions, either prior to screening phase or following implantation of infusion device.113 Monitor patient carefully; avoid abrupt dosage reduction or discontinuance of concomitant antispasmodics.113


Presence of Infection

Presence of infection may interfere with assessment of the patient's response to baclofen test dose(s),113 increase surgical complications after pump implantation, and complicate attempts to adjust dosage.113 115


Patients being considered for intrathecal baclofen therapy should be without concurrent infection.113


Ovarian Cysts

Ovarian cysts found in about 4% of multiple sclerosis patients receiving oral baclofen for up to 1 year; cysts disappeared spontaneously despite continued baclofen use in most patients.113 128 Estimated rate of occurrence in healthy females is approximately 1–5%.113 128


Specific Populations


Pregnancy

Category C.113


Lactation

Distributed into milk following oral administration; not known whether baclofen distributes into milk following intrathecal administration.113


Nursing not recommended in women receiving oral baclofen.128 Women receiving intrathecal baclofen should nurse infant only if potential benefit justifies potential risks to infant.113


Pediatric Use

Safety and efficacy of oral baclofen not established in children <12 years of age; use not recommended.128


Safety and efficacy of intrathecal baclofen not established in children <4 years of age.113


Children being considered for intrathecal therapy should have sufficient body mass to accommodate the pump.113 Consult directions provided by the device’s manufacturer.113


Renal Impairment

Excreted principally in urine as unchanged drug; use with caution in patients with impaired renal function.113 128 (See Renal Impairment under Dosage and Administration.)


Common Adverse Effects


For oral baclofen, drowsiness, dizziness, weakness, fatigue.128


For intrathecal baclofen in patients with spasticity of spinal cord origin, somnolence, dizziness, nausea, hypotension, headache, seizures, hypotonia.113


For intrathecal baclofen in patients with spasticity of cerebral origin, agitation, constipation, somnolence, leukocytis, chills, urinary retention, hypotonia.113


Interactions for Lioresal


Specific Drugs









Drug



Interaction



CNS depressants (e.g., alcohol)



Additive CNS depression.113 128



Morphine (epidural)



Hypotension and dyspnea may occur when administered with intrathecal baclofen.113


Lioresal Pharmacokinetics


Absorption


Bioavailability


Rapidly and almost completely absorbed following oral administration,128 with peak blood concentrations attained within 2–3 hours.b


Following intrathecal administration, plasma concentrations are 100 times less than those achieved following oral administration.113


Onset


Oral administration: Onset in hours to weeks.b


Intrathecal injection: Onset in 0.5–1 hour; peak effect in about 4 hours.113


Continuous intrathecal infusion: Onset at 6–8 hours; peak effect at 24–48 hours.113


Onset and peak response may vary depending on dose and severity of symptoms.113


Duration


Following intrathecal injection, effects may last 4–8 hours.113 Duration may vary depending on dose and severity of symptoms.113


Distribution


Extent


Widely distributed following oral administration, but only small amounts cross the blood-brain barrier.8 16 109 b


Crosses the placentab and distributes into milk following oral administration.113


Plasma Protein Binding


30%.b


Elimination


Metabolism


About 15% of a dose is metabolized in the liver, mostly by deamination.b


Elimination Route


Excreted mainly (70–80%) in urine as unchanged drug or metabolites; remainder is excreted in feces.b


Half-life


Serum half-life: 2.5–4 hours.b


CSF elimination half-life: 1.51 hours for the first 4 hours following intrathecal injection.113 Following intrathecal administration, CSF clearance of baclofen approximates CSF turnover.113


Stability


Storage


Oral


Tablets

Tight containers at 15–30°C.128


Parenteral


Injection

≤30°C.113 Refrigeration not required.113 Do not freeze or autoclave.113


Compatibility


For information on systemic interactions resulting from concomitant use, see Interactions.


Parenteral


Solution Compatibility113




Compatible



Sodium chloride 0.9%


Drug Compatibility





Admixture CompatibilityHID

Compatible



Clonidine HCl



Morphine sulfate


ActionsActions



  • Decreases frequency and amplitude of muscle spasms (tonic reflexes) that arise in response to muscle stretching in patients with various spinal cord lesions.b




  • Simultaneously and equally suppresses cutaneous reflexes and muscle tone but only slightly depresses amplitude of tendon jerks (phasic reflexes).b




  • Inhibits both monosynaptic and polysynaptic reflexes at the spinal level, possibly by decreasing excitatory neurotransmitter release from primary afferent terminals; actions at supraspinal sites also may occur and contribute to drug's clinical effect.113 128




  • Intrathecal administration in animals increases antinociception and decreases muscle rigidity and spasticity.106 107 108



Advice to Patients



  • Importance of not abruptly discontinuing therapy.113 128 For patients receiving intrathecal baclofen, importance of keeping scheduled refill visits and of recognizing early signs and symptoms of withdrawal.113




  • If baclofen is to be administered intrathecally, risks associated with intrathecal baclofen therapy, recognition and management of overdosage, and proper care of pump and catheter insertion site.113




  • Risk of drowsiness; exercise caution when driving or operating machinery.113 128




  • Potential for additive CNS depression if other CNS depressants (e.g., alcohol) are used concomitantly.113 128




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.113 128




  • Importance of women informing their clinician if they are or plan to become pregnant or to breast-feed.113 128




  • Importance of informing patients of other important precautionary information. (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

































Baclofen

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets



10 mg*



Baclofen (with povidone; scored)



Alpharma, Major, Teva, Upsher-Smith, Vintage, Watson



20 mg*



Baclofen (with povidone; scored)



Alpharma, Major, Teva, Upsher-Smith, Vintage, Watson



Parenteral



For injection concentrate, for intrathecal administration via compatible infusion device or for intrathecal injection



50 mcg/mL



Lioresal Intrathecal (additive-free)



Medtronic



0.5 mg/mL



Lioresal Intrathecal (additive-free)



Medtronic



2 mg/mL



Lioresal Intrathecal (additive-free)



Medtronic


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Baclofen 10MG Tablets (UPSHER-SMITH): 30/$13.99 or 90/$34.98


Baclofen 20MG Tablets (UPSHER-SMITH): 30/$17.99 or 90/$45.97



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions August 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References


Only references cited for selected revisions after 1984 are available electronically.



7. Hudgson P, Weightman D. Baclofen in the treatment of spasticity. Br Med J. 1971; 4:15-7. [IDIS 21127] [PubMed 4938243]



8. Anon. Control of spasticity. Br Med J. 1973; 4:751-2. [PubMed 4758569]



13. Jones RF, Lance JW. Baclofen (Lioresal) in the long-term management of spasticity. Med J Aust. 1976; 1:654-7. [IDIS 70798] [PubMed 820953]



14. Duncan GW, Shahani BT, Young RR. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. Neurology. 1976; 28:441-6.



16. Brogden RN, Speight TM, Avery GS. Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity. Drugs. 1974; 8:1-14. [IDIS 47602] [PubMed 4154834]



106. Yaksh TL, Reddy SVR. Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, α-adrenergic agonists and baclofen. Anesthesiology. 1981; 54:451-67. [PubMed 6112935]



107. Wilson PR, Yaksh TL. Baclofen is antinociceptive in the spinal intrathecal space of animals. Eur J Pharm. 1978; 51:323-30.



108. Sawynok J, Dickson C. D-Baclofen is an antagonist at baclofen receptors mediating antinociception in the spinal cord. Pharmacology. 1985; 31:248-59. [PubMed 2999839]



109. Knutsson E, Lindblom U, Martensson A. Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci. 1974; 23:473-84. [PubMed 4154365]



110. Penn RD, Savoy SM, Corcos D et al. Intrathecal baclofen for severe spinal spasticity. New Engl J Med. 1989; 320:1517-21. [IDIS 254995] [PubMed 2657424]



111. Medtronic, Inc, Boston, MA: Personal communication.



112. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food Drug and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414), to June 28, 1996. Rockville, MD; 1996 Jul.



113. Medtronic Inc. Lioresal intrathecal (baclofen injection) prescribing information. Minneapolis, MN; 2002 Nov.



114. Penn RD, Kroin JS. Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg. 1987; 66:181-5. [PubMed 3806200]



115. Medtronic Inc. Lioresal (baclofen) intrathecal injection SynchroMed infusion pump product monograph. Minneapolis, MN; 1992 (UC9202606EN NP-1564)



116. Parke B, Penn RD, Savoy SM et al. Functional outcome after delivery of intrathecal baclofen. Acta Phys Med Rehabil. 1989; 70:30-2.



117. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg. 1992; 77:236-40. [PubMed 1625011]



118. Kravitz HM, Corcos DM, Hansen G et al. Intrathecal baclofen. Effects on nocturnal leg muscle spasticity. Am J Phys Med Rehabil. 1992; 71:48-52. [PubMed 1739446]



119. Latash ML, Penn RD, Corcos DM et al. Effects of intrathecal baclofen on voluntary motor control in spastic paresis. J Neurosurg. 1990; 72:388-92. [PubMed 2303873]



120. Latash ML, Penn RD, Corcos DM et al. Short-term effects of intrathecal baclofen in spasticity. Exp Neurol. 1989; 103:165-72. [PubMed 2912760]



121. Albright AL, Barron WB, Fasick MP et al. Continuous intrathecal baclofen infusion for spasticity of cerebral origin.



122. Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA. 1991; 265:1418-22. [IDIS 279342] [PubMed 1999883]



123. Lazorthes Y, Sallerin-Caute B, Verdie JC et al. Chronic intrathecal baclofen administration for control of severe spasticity. J Neurosurg. 1990; 72:393-402. [PubMed 2303874]



124. Rifici C, Kofler M, Kronenberg M et al. Intrathecal baclofen application in patients with supraspinal spasticity secondary to severe traumatic brain injury. Funct Neurol. 1994; 9:29-34. [PubMed 8082851]



125. Medtronic Inc., Minneapolis, MN: Personal communication.



126. Medtronic Inc. Investigation of the administration of Lioresal intrathecal (baclofen injection) for the management of spasticity of cerebral origin: treatment IND protocol. Protocol No. NVD94-043/version 1.1a. Minneapolis, MN: Medtronic Inc; 1994 Dec.



127. Geigy. Lioresal (baclofen) tablets prescribing information. Summit, NJ; 1996 Mar.



128. Watson Laboratories, Inc. Baclofen tablets, USP prescribing information. Corona, CA; 1998 Apr.



b. AHFS drug information 2003. McEvoy GK, ed. Baclofen. Bethesda, MD: American Society of Health-System Pharmacists; 2003:1314-8.



HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:204-5.



More Lioresal resources


  • Lioresal Side Effects (in more detail)
  • Lioresal Use in Pregnancy & Breastfeeding
  • Drug Images
  • Lioresal Drug Interactions
  • Lioresal Support Group
  • 5 Reviews for Lioresal - Add your own review/rating


  • Lioresal Advanced Consumer (Micromedex) - Includes Dosage Information

  • Lioresal Prescribing Information (FDA)

  • Lioresal MedFacts Consumer Leaflet (Wolters Kluwer)

  • Baclofen Prescribing Information (FDA)

  • Baclofen Professional Patient Advice (Wolters Kluwer)

  • Gablofen Advanced Consumer (Micromedex) - Includes Dosage Information

  • Gablofen Prescribing Information (FDA)

  • Gablofen Consumer Overview

  • Lioresal Intrathecal Prescribing Information (FDA)



Compare Lioresal with other medications


  • Alcohol Withdrawal
  • Cerebral Spasticity
  • Cervical Dystonia
  • Dystonia
  • Hiccups
  • Huntington's Disease
  • Migraine Prevention
  • Muscle Spasm
  • Muscle Twitching
  • Neuralgia
  • Periodic Limb Movement Disorder
  • Spasticity
  • Trigeminal Neuralgia

Tolcapone


Pronunciation: TOLE-ka-pone
Generic Name: Tolcapone
Brand Name: Tasmar

Severe and possibly fatal liver problems may occur in patients who take Tolcapone. Tolcapone should only be used in certain patients who cannot take or have not responded to other treatments. Patients who do not show an improvement in their symptoms after taking Tolcapone for at least 3 weeks should stop taking it due to possible risk of liver injury. Patients who have liver disease or have had 2 abnormal liver function tests should not start taking Tolcapone. Liver function tests will be performed before and during treatment to monitor side effects. However, these tests may not decrease the risk of developing serious liver problems. Make sure to keep all doctor and lab appointments. Contact your doctor at once if you develop dark urine, loss of appetite, pale stools, right-sided stomach pain, severe or persistent nausea or tiredness, sluggishness, or yellowing of the skin or eyes. Patients who develop liver problems while taking Tolcapone should not take Tolcapone again.


Patients who have a history of severe uncontrolled muscle movement (eg, jerking, twitching) should use Tolcapone with extreme caution.





Tolcapone is used for:

Treating Parkinson disease. It is used along with levodopa/carbidopa. It is only used in patients who cannot take or have not responded to other medications.


Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor. It works by prolonging the anti-Parkinson effect action of levodopa.


Do NOT use Tolcapone if:


  • you are allergic to any ingredient in Tolcapone

  • you have liver disease or have had 2 abnormal liver function tests

  • you had to stop taking Tolcapone before because of liver problems

  • you have a history of certain muscle problems (rhabdomyolysis) or fever and confusion that may have been caused by Tolcapone

  • you are taking a nonselective monoamine oxidase inhibitor (MAOI) (eg, phenelzine)

Contact your doctor or health care provider right away if any of these apply to you.



Before using Tolcapone:


Some medical conditions may interact with Tolcapone. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of kidney problems, liver problems (eg, cirrhosis), or abnormal liver function tests

  • if you have a history of severe, uncontrolled muscle movements (eg, uncontrolled jerking, twitching) or a certain severe muscle problem (rhabdomyolysis)

  • if you experience dizziness or lightheadedness when you stand up

Some MEDICINES MAY INTERACT with Tolcapone. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Warfarin because the risk of bleeding may be increased

  • Desipramine or nonselectiveMAOIs (eg, phenelzine) because they may increase the risk of Tolcapone's side effects

  • Apomorphine, dobutamine, isoproterenol, levodopa, methyldopa, or a sympathomimetic (eg, albuterol, pseudoephedrine) because the risk of their side effects may be increased by Tolcapone

This may not be a complete list of all interactions that may occur. Ask your health care provider if Tolcapone may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Tolcapone:


Use Tolcapone as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Tolcapone by mouth with or without food.

  • Do not suddenly stop taking Tolcapone. You may have an increased risk of Parkinson disease symptoms, fever, confusion, or muscle rigidity. If you need to stop Tolcapone or add a new medicine, your doctor will gradually lower your dose.

  • If you miss a dose of Tolcapone, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Tolcapone.



Important safety information:


  • You must discuss the benefits and risks of Tolcapone with your doctor and sign a patient acknowledgment form before you begin treatment with Tolcapone.

  • Tolcapone may cause drowsiness, dizziness, or lightheadedness. These effects may be worse if you take it with alcohol or certain medicines. Use Tolcapone with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Do not drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Tolcapone; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.

  • Tolcapone may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.

  • If your symptoms do not get better within 3 weeks or if they get worse, check with your doctor.

  • Some patients who take Tolcapone may develop certain muscle movements that they cannot control. Tell your doctor at once if you have new or worsening muscle problems with your arms, legs, or your face, mouth, or jaw (eg, tongue sticking out, puffing of cheeks, mouth puckering, chewing movements) while you take Tolcapone.

  • Tolcapone may cause nausea or diarrhea. Nausea may be more likely when you first start taking Tolcapone. If nausea or diarrhea occurs, discuss with your doctor ways to lessen the effects.

  • Some people have experienced new, unusual, or increased urges (eg, gambling, sexual urges) while using Tolcapone. Tell your doctor right away if you notice such effects.

  • Patients with Parkinson disease may have an increased risk of developing a certain type of skin cancer (melanoma). It is not known if Tolcapone also increases the risk of melanoma. You may need to have skin exams while you are using Tolcapone. Tell your doctor if you notice any unusual skin growths or a change in the appearance of a mole. Discuss any questions or concerns with your doctor.

  • Use Tolcapone with caution in the ELDERLY; they may be more sensitive to its effects, especially hallucinations.

  • Lab tests, including liver function tests, may be performed while you use Tolcapone. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Tolcapone is not recommended for use in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Tolcapone while you are pregnant. It is not known if Tolcapone is found in breast milk. If you are or will be breast-feeding while you use Tolcapone, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Tolcapone:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; diarrhea; dizziness; drowsiness; dry mouth; gas; headache; increased sweating; lightheadedness when sitting up or standing; nausea; stomach upset; trouble sleeping; unusual or excessive dreams; upper respiratory tract infection; urine discoloration; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blood in the urine; chest pain; confusion; fainting; falling; fever; hallucinations; mental or mood changes; muscle pain (with or without fever or confusion); new or worsening uncontrolled muscle movements of the arms or legs, or of the tongue face, mouth, or jaw (eg, tongue sticking out, puffing of cheeks, mouth puckering, chewing movements); rigid muscles; severe or persistent diarrhea; shortness of breath; symptoms of liver problems (eg, dark urine, loss of appetite, pale stools, right-sided stomach pain, severe or persistent nausea or tiredness, sluggishness, yellowing of the skin or eyes).



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Tolcapone side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include dizziness; nausea; vomiting.


Proper storage of Tolcapone:

Store Tolcapone at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Tolcapone out of the reach of children and away from pets.


General information:


  • If you have any questions about Tolcapone, please talk with your doctor, pharmacist, or other health care provider.

  • Tolcapone is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Tolcapone. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Tolcapone resources


  • Tolcapone Side Effects (in more detail)
  • Tolcapone Use in Pregnancy & Breastfeeding
  • Tolcapone Drug Interactions
  • Tolcapone Support Group
  • 0 Reviews for Tolcapone - Add your own review/rating


  • Tolcapone Monograph (AHFS DI)

  • Tolcapone Professional Patient Advice (Wolters Kluwer)

  • tolcapone Concise Consumer Information (Cerner Multum)

  • tolcapone Advanced Consumer (Micromedex) - Includes Dosage Information

  • Tasmar Prescribing Information (FDA)



Compare Tolcapone with other medications


  • Parkinson's Disease

Tuesday, 4 September 2012

FemTab Sequi





1. Name Of The Medicinal Product



FemTab Sequi


2. Qualitative And Quantitative Composition



- Each white sugar-coated tablet contains:



Estradiol valerate 2.0mg



- Each pink sugar-coated tablet contains:



Estradiol valerate 2.0mg



Levonorgestrel 75 micrograms



3. Pharmaceutical Form



Sugar coated tablets for oral use.



4. Clinical Particulars



4.1 Therapeutic Indications



Hormone replacement therapy for the treatment of the climacteric syndrome.



Second line therapy for prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.



For maximum prophylactic benefit treatment should commence as soon as possible after the menopause.



Bone mineral density measurements may help to confirm the presence of low bone mass.



FemTab Sequi is designed to provide hormone replacement therapy during and after the climacteric. The addition of a progestogen in the second half of each course helps to provide good control of the irregular cycles that are characteristic of the premenopausal phase and opposes the production of endometrial hyperplasia. Whilst ovarian hormone production is little affected, FemTab Sequi abolishes or improves the characteristic symptoms of the climacteric such as hot flushes, sweating attacks and sleep disorders.



Studies of bone mineral content have shown FemTab Sequi to be effective in the prevention of progressive bone loss following the menopause.



FemTab Sequi does not consistently inhibit ovulation and is therefore unsuitable for contraception.



4.2 Posology And Method Of Administration



Adults, including the elderly:



If the patient is still menstruating, treatment should begin on the 5th day of menstruation. Patients whose periods are very infrequent or who are postmenopausal may start at any time, provided pregnancy has been excluded (see Section 4.4. Special warnings and special precautions for use).



One white tablet is taken daily for the first 16 days, followed by one pink tablet daily for 12 days. Thus, each pack contains 28 days treatment. Treatment is continuous, which means that the next pack follows immediately without a break. Bleeding usually occurs within the last few days of one pack and the first week of the next.



4.3 Contraindications



- Pregnancy (See Section 4.4. Special warnings and special precautions for use)



- severe disturbances of liver function



- previous or existing liver tumours



- jaundice or general pruritus during a previous pregnancy



- Dubin-Johnson syndrome



- Rotor syndrome



- active deep venous thrombosis, thromboembolic disorders, or a history of confirmed venous thromboembolism. (See also Special warnings and special precautions for use).



- sickle-cell anaemia



- suspected or existing hormone-dependent disorders or tumours of the uterus and breast



- undiagnosed irregular vaginal bleeding



- congenital disturbances of lipid metabolism



- a history of herpes gestationis



- otosclerosis with deterioration in previous pregnancies



- endometriosis



- severe diabetes with vascular changes



- mastopathy.



4.4 Special Warnings And Precautions For Use



Assessment of each woman prior to taking hormone replacement therapy (and at regular intervals thereafter) should include a personal and family medical history. Physical examination should be guided by this and by the contraindications (section 4.3) and warnings (section 4.4) for FemTab Sequi. During assessment of each individual woman clinical examination of the breasts and pelvic examination should be performed where clinically indicated rather than as a routine procedure. Women should be encouraged to participate in the national breast cancer screening programme (mammography) and the national cervical cancer screening programme (cervical cytology) as appropriate for their age. Breast awareness should also be encouraged and women advised to report any changes in their breasts to their doctor or nurse.



Before starting treatment, pregnancy must be excluded. If the expected bleeding fails to occur at about 28-day intervals, treatment should be stopped until pregnancy has been ruled out.



Persistent breakthrough bleeding during treatment is an indication for endometrial assessment which may include biopsy.



Epidemiological studies have suggested that hormone replacement therapy (HRT) is associated with an increased relative risk of developing venous thromboembolism (VTE) i.e. deep vein thrombosis or pulmonary embolism. The studies find a 2-3 fold increase for users compared with non-users which for healthy women amounts to a low risk of one extra case of VTE each year for every 5000 patients taking HRT.



Generally recognised risk factors for VTE include a personal or family history and severe obesity (Body Mass Index>30 kg/m2). In women with these factors the benefits of treatment with HRT need to be carefully weighed against risks. There is no consensus about the possible role of varicose veins in VTE.



The risk of VTE may be temporarily increased with prolonged immobilisation, major trauma or major surgery. In women on HRT scrupulous attention should be given to prophylactic measures to prevent VTE following surgery. Where prolonged immobilisation is liable to follow elective surgery, particularly abdominal or orthopaedic surgery to the lower limbs, consideration should be given to temporarily stopping HRT 4 weeks earlier, if this is possible.



If venous thromboembolism develops after initiating HRT the drug should be discontinued.



Prolonged exposure to unopposed oestrogens increases the risk of development of endometrial carcinoma. The general consensus of opinion is that the addition of 12 days progestogen towards the end of the cycle, as in FemTab Sequi, diminishes the possibility of such a risk, and some investigators consider that it might be protective.



A reanalysis of original data from 51 epidemiological studies reported a small or moderate increase in the probability of having breast cancer diagnosed in women currently or recently using HRT. The findings may be due to biological effects of HRT, earlier diagnosis, or a combination of both. The relative risk increased with duration of treatment (by 2.3% per year of use) and returned to normal in the course of five years after cessation of HRT use. This increase in relative risk associated with duration of HRT use is comparable to the increase in relative risk when natural menopause is delayed in the absence of HRT (2.8% increase for each year older at menopause). Breast cancers diagnosed in current or recent users of HRT are more likely to be localised to the breast than those found in non-users. HRT use may not be associated with increased mortality from breast cancer.



Between the ages of 50 and 70, about 45 women in every 1000 not using HRT will have breast cancer diagnosed. It is estimated that among those who use HRT for 5 years starting at age 50, 2 extra cases of breast cancer will be detected by age 70 in every 1000 women. For those who use HRT for 10 years there will be 6 extra cases of breast cancer, and for 15 years use, 12 extra cases of breast cancer in every 1000 women during the 20 year period until age 70.



It is important that the increased risk of being diagnosed with breast cancer is discussed with the patient and weighed against the known benefits of HRT.



Treatment should be stopped at once if migrainous or frequent and unusually severe headaches occur for the first time, or if there are other symptoms that are possible prodromata of vascular occlusion.



Treatment should be stopped at once if jaundice or pregnancy occurs, if there is a significant rise in blood pressure, or an increase in epileptic seizures.



Some women are predisposed to cholestasis during steroid therapy. Diseases that are known to be subject to deterioration during pregnancy (e.g. multiple sclerosis, epilepsy, diabetes, benign breast disease, hypertension, cardiac or renal dysfunction, asthma, porphyria, tetany and otosclerosis) and women with a strong family history of breast cancer should be carefully observed during treatment.



Pre-existing fibroids may increase in size under the influence of oestrogens. If this is observed treatment should be discontinued.



In patients with mild chronic liver disease, liver function should be checked every 8 - 12 weeks.



In rare cases benign and, in even rarer cases, malignant liver tumours leading in isolated cases to life-threatening intra-abdominal haemorrhage have been observed after the use of hormonal substances such as those contained in FemTab Sequi. If severe upper abdominal complaints, enlarged liver, or signs of intra-abdominal haemorrhage occur, a liver tumour should be included in the differential diagnostic considerations.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Hormonal contraception should be stopped when treatment with FemTab Sequi is started and the patient should be advised to take non-hormonal contraceptive precautions.



Drugs which induce hepatic microsomal enzyme systems e.g. barbiturates, phenytoin, rifampicin, accelerate the metabolism of oestrogen/progestogen combinations such as FemTab Sequi and may reduce their efficacy.



The requirement for oral antidiabetics or insulin can change.



4.6 Pregnancy And Lactation



Contra-indicated.



4.7 Effects On Ability To Drive And Use Machines



None known.



4.8 Undesirable Effects



During the first few months of treatment, breakthrough bleeding, spotting and breast tenderness or enlargement can occur. These are usually temporary and normally disappear after continued treatment. Other symptoms known to occur are: anxiety; increased appetite; bloating; palpitations; depressive symptoms; headache; migraine; dizziness; dyspepsia; leg pains; oedema; altered libido; nausea; rashes; vomiting; altered weight; chloasma.



4.9 Overdose



There have been no reports of ill-effects from overdosage, which it is, therefore, generally unnecessary to treat. There are no specific antidotes, and treatment should be symptomatic.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



FemTab Sequi contains estradiol valerate (the valeric acid ester of the endogenous female oestrogen, estradiol) and the synthetic progestogen, levonorgestrel. Estradiol valerate provides hormone replacement during and after the climacteric. The addition of levonorgestrel in the second half of each course of tablets helps to provide good cycle control and opposes the development of endometrial hyperplasia.



Most studies show that oral administration of estradiol valerate to post-menopausal women increases serum high density lipoprotein cholesterol (HDL-C) and decreases low density lipoprotein cholesterol (LDL-C). Although epidemiological data are limited such alterations are recognised as potentially protective against the development of arterial disease. A possible attenuation of these effects may occur with the addition of a progestogen. However, at the doses used in FemTab Sequi, the 12 days of combined therapy with estradiol valerate and levonorgestrel have not been observed to be associated with any unwanted lipid effects.



5.2 Pharmacokinetic Properties



1. Levonorgestrel (LNG)



Orally administered LNG is rapidly and completely absorbed. Following ingestion of one tablet of FemTab Sequi maximum drug serum levels of 1.9ng/ml were found at 1.3 hours. Thereafter, LNG serum levels decrease in two disposition phases. The first phase is described by a half-life of 0.5-1.5 hours and the terminal phase by a half-life of 20-27 hours. For LNG, a metabolic clearance rate from serum of about 1.5 ml/min/kg was determined. LNG is not excreted in unchanged form but as metabolites. LNG metabolites are excreted at about equal proportions with urine and faeces. The biotransformation follows the known pathways of steroid metabolism. No pharmacologically active metabolites are known.



LNG is bound to serum albumin and to SHBG. Only about 1.5% of the total serum drug levels are present as free steroid, but 65% are specifically bound to SHBG. The relative distribution (free, albumin-bound, SHBG-bound) depends on the SHBG concentrations in the serum. Following induction of the binding protein, the SHBG bound fraction increases while the unbound and the albumin-bound fraction decrease.



Following daily repeated administration, LNG concentrations in the serum increase by a factor of about 2. Steady-state conditions are reached within a few days. The pharmacokinetics of LNG is influenced by SHBG serum levels. Under treatment with FemTab Sequi SHBG levels will rise by about 40% during the oestrogen phase and remain constant or slightly decrease thereafter. The absolute bioavailability of LNG was determined to be almost 100% of the dose administered. The relative bioavailability was tested against an aqueous microcrystalline suspension and was found to be complete (108%).



About 0.1% of the maternal dose can be transferred via milk to the nursed infant.



2. Estradiol valerate (E2 val)



E2 val is completely absorbed from the FemTab Sequi tablet. During absorption and the first passage through the liver the steroid ester is cleaved into estradiol (E2) and valeric acid. At the same time E2 undergoes extensive further metabolism yielding E2 conjugates, estrone (E1) and E1 conjugates. The pharmacologically most active metabolites of E2 val are E2 and E1. Maximum serum levels of 25 pg E2/ml and 180 pg E1/ml are reached 5-7 hours after the administration of one FemTab Sequi tablet.



Mean E1 serum levels are 10-12 fold higher than mean E2 serum concentrations. Serum levels of E1 conjugates are about 25 fold higher than the E1 serum levels.



E2 is rapidly metabolised and the metabolic clearance rate has been determined to 30ml/min/kg. After oral intake of E2 the half-life of the terminal disposition phase was about 13 hours for E2. The respective half-life for E1 serum level decline was about 20 hours. The daily use of FemTab Sequi will lead to an about 50% increase in E2 serum levels and to twofold E1 levels at steady state.



Estradiol is bound to about 97% to serum proteins, about 35% are specifically bound to SHBG. E2- val is not excreted in unchanged form. The metabolites of estradiol are excreted via urine and bile with a half-life of about 1 day at a ratio of 9:1.



The absolute bioavailability of E2 from E2 val is about 3% of oral dose and thus in the same range like oral E2 (5% of dose).



The relative bioavailability of E2 val (reference: aqueous microcrystalline suspension) from FemTab Sequi tablets was complete (111-112%).



Estradiol and its metabolites are excreted into milk only to a minor extent.



5.3 Preclinical Safety Data



There are no preclinical data which could be of relevance to the prescriber and which are not already included in other relevant sections of the SPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



FemTab Sequi contains the following excipients: lactose, maize starch, povidone 25 000, povidone 700 000, talcum, magnesium stearate (E572), sucrose, macrogol 6000 (polyethylene glycol 6000), calcium carbonate (E170), glycerol (E422), montan glycol wax, yellow and red ferric oxide pigments (E172), titanium dioxide (E171).



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



5 years.



6.4 Special Precautions For Storage



None.



6.5 Nature And Contents Of Container



Packs containing aluminium foil and PVC blister strips.



Presentation:



Carton containing memo-packs of either 1 x 28 tablets or 3 x 28 tablets.



6.6 Special Precautions For Disposal And Other Handling



Not applicable.



7. Marketing Authorisation Holder



Schering Health Care Limited



The Brow



Burgess Hill



West Sussex RH15 9NE



8. Marketing Authorisation Number(S)



PL 0053/0219



9. Date Of First Authorisation/Renewal Of The Authorisation



7th October 1991/26th March 1997



10. Date Of Revision Of The Text



9 December 2003




Saturday, 1 September 2012

Itraconal




Itraconal may be available in the countries listed below.


Ingredient matches for Itraconal



Itraconazole

Itraconazole is reported as an ingredient of Itraconal in the following countries:


  • Greece

International Drug Name Search